| Literature DB >> 19580950 |
Matthew P Gilbert1, Richard E Pratley.
Abstract
This article aims to provide an overview of efficacy and safety data on glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors in the treatment of type 2 diabetes mellitus. Our goal is to differentiate the clinical profiles of GLP-1 receptor agonists and DPP-4 inhibitors, as well as the individual agents within each class. Additionally, we examine the utility of GLP-1 receptor agonists and DPP-4 inhibitors as these agents may be applied at different stages of type 2 diabetes therapy and discuss recently published clinical findings and their implications for treatment.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19580950 DOI： 10.1016/j.ejim.2009.05.011
Source DB: PubMed Journal: Eur J Intern Med ISSN： 0953-6205 Impact factor: 4.487